These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33601187)

  • 1. Synthesis and preliminary evaluation of
    Vaidyanathan G; Mease RC; Minn I; Choi J; Chen Y; Shallal H; Kang CM; McDougald D; Kumar V; Pomper MG; Zalutsky MR
    Nucl Med Biol; 2021; 94-95():67-80. PubMed ID: 33601187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
    Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR
    Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
    Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
    J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A third generation PSMA-targeted agent [
    Feng Y; Meshaw RL; Finch SW; Zheng Y; Minn I; Vaidyanathan G; Pomper MG; Zalutsky MR
    Nucl Med Biol; 2024; 134-135():108916. PubMed ID: 38703587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics.
    Huynh TT; Feng Y; Meshaw R; Zhao XG; Rosenfeld L; Vaidyanathan G; Papo N; Zalutsky MR
    Nucl Med Biol; 2024; 134-135():108913. PubMed ID: 38703588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Wüstemann T; Barelli P; Kim D; Williams C; Zheng X; Bi C; Hu B; Warren JD; Hage DS; DiMagno SG; Babich JW
    J Nucl Med; 2017 Sep; 58(9):1442-1449. PubMed ID: 28450562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Improved
    Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
    J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
    Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
    J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.
    Shimizu Y; Ando M; Watanabe H; Ono M
    Ann Nucl Med; 2024 Oct; 38(10):847-851. PubMed ID: 38976087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
    Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
    Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosynthesis and biological evaluation of 18F-labeled bispecific heterodimer targeted dual gastrin-releasing peptide receptor and prostate-specific membrane antigen for prostate cancer imaging.
    Ye S; Li H; Hu K; Li L; Zhong J; Yan Q; Wang Q
    Nucl Med Commun; 2022 Mar; 43(3):323-331. PubMed ID: 34919064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of
    Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
    Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Duan X; Cao Z; Zhu H; Liu C; Zhang X; Zhang J; Ren Y; Liu F; Cai X; Guo X; Xi Z; Pomper MG; Yang Z; Fan Y; Yang X
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1030-1040. PubMed ID: 34453203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen.
    Lewis MR; Schaedler AW; Ho KV; Golzy M; Mathur A; Pun M; Gallazzi F; Watkinson LD; Carmack TL; Sikligar K; Anderson CJ; Smith CJ
    Nucl Med Biol; 2024; 136-137():108938. PubMed ID: 39032262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.